

PRESS RELEASE

Hit Discovery Constance GmbH announces the appointment of Dr. Thilo Enderle as Chief Executive Officer

January 10th, 2019 - Constance (Germany) - Hit Discovery Constance (HDC), a joint venture company held by Axxam SpA (Milan, Italy), the Centre for Drug Design and Discovery (CD3) of KU Leuven (Leuven, Belgium) and Lead Discovery Center GmbH (Dortmund, Germany) announced today that Dr. Thilo Enderle has been appointed as Chief Executive Officer. Thilo brings to HDC more than 20 years of industry experience spanning from target discovery to lead generation and preclinical candidate nomination in both large Pharmaceutical and Biotech companies.

Most recently Thilo was collaborating with various academic groups, biotechnology start-ups and CROs in Asia, Europa and the US. In this role he was also Head of Discovery at E-Scape Bio, a biopharmaceutical company in South San Francisco focusing on novel therapies to treat genetically defined neurodegenerative diseases.

Prior to this position he was Senior Research Director at F. Hoffmann-La Roche in Basel where he led an interdisciplinary team in a global matrix organization. With the team he was driving more than 100 projects in various disease areas (Neuroscience, Ophthalmology, Virology, Oncology and Metabolic Diseases) from target assessment to lead optimization. Thanks to the high success rate and quality of their assays and screens, several of the lead compounds generated by Thilo and his team reached late clinical stage and are still active programs.

Thilo is an inventor on 12 patent applications for proprietary assay methods and laboratory automation solutions. Three of his inventions have been commercialized.

Thilo Enderle said: *"I am very happy to join HDC in Constance and to be part of this great team. After my early days in Big Pharma and recently the experience of the Biotech environment, this position will give me yet another exciting view on drug discovery. I look forward to contributing to the success of our clients, in our partnerships we will pave the way for innovative solutions across all life sciences"*.

Alessandro Sidoli, Chairman of the Shareholders Meeting at HDC said: *"We all are extremely pleased to have Thilo joining HDC. His significant scientific and industrial experience in early drug discovery is very important for the further development of HDC towards a relevant screening hub based in the middle of Europe serving both academic and industrial clients"*.

About Hit Discovery Constance GmbH

Hit Discovery Constance GmbH (HDC) is a joint venture company held by Axxam SpA (Milan, Italy), the Centre for Drug Design and Discovery of KU Leuven (Leuven, Belgium) and Lead Discovery Center GmbH (Dortmund, Germany). The Company is a qualified provider of discovery services including high-throughput screening with different formats (including fluorescence, luminescence, radiometric), high content screening, compound profiling, compound storage and management services for the life sciences industry. More information on www.hit-discovery.com.